Equities Analysts Offer Predictions for RANI FY2025 Earnings

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) – Investment analysts at Zacks Small Cap upped their FY2025 earnings estimates for shares of Rani Therapeutics in a research note issued on Tuesday, April 1st. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will post earnings of ($0.74) per share for the year, up from their prior estimate of ($0.89). The consensus estimate for Rani Therapeutics’ current full-year earnings is ($1.01) per share. Zacks Small Cap also issued estimates for Rani Therapeutics’ FY2026 earnings at ($0.64) EPS.

A number of other equities analysts have also recently commented on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $9.00 target price on shares of Rani Therapeutics in a research report on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Rani Therapeutics in a report on Thursday. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Rani Therapeutics currently has an average rating of “Buy” and a consensus price target of $12.33.

Rani Therapeutics Trading Up 13.0 %

RANI stock opened at $1.39 on Thursday. Rani Therapeutics has a one year low of $1.20 and a one year high of $8.75. The company has a market capitalization of $79.63 million, a PE ratio of -1.31 and a beta of 0.14. The company’s 50 day moving average price is $1.51 and its two-hundred day moving average price is $1.82. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.60 and a current ratio of 1.60.

Rani Therapeutics (NASDAQ:RANI) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). The company had revenue of $1.03 million during the quarter.

Institutional Investors Weigh In On Rani Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Two Sigma Investments LP purchased a new position in shares of Rani Therapeutics during the fourth quarter valued at approximately $399,000. Takeda Pharmaceutical Co. Ltd. bought a new stake in Rani Therapeutics in the fourth quarter valued at $278,000. Stifel Financial Corp increased its position in Rani Therapeutics by 100.4% during the 3rd quarter. Stifel Financial Corp now owns 269,768 shares of the company’s stock valued at $583,000 after purchasing an additional 135,148 shares during the period. Two Sigma Advisers LP bought a new position in Rani Therapeutics in the 4th quarter worth $151,000. Finally, Insigneo Advisory Services LLC purchased a new position in shares of Rani Therapeutics during the fourth quarter valued at about $65,000. Hedge funds and other institutional investors own 30.19% of the company’s stock.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.